160 related articles for article (PubMed ID: 12213403)
1. Cost-effectiveness of measles elimination in Latin America and the Caribbean: a prospective analysis.
Acharya A; Diaz-Ortega JL; Tambini G; de Quadros C; Arita I
Vaccine; 2002 Sep; 20(27-28):3332-41. PubMed ID: 12213403
[TBL] [Abstract][Full Text] [Related]
2. Assessing the cost-effectiveness of different measles vaccination strategies for children in the Democratic Republic of Congo.
Doshi RH; Eckhoff P; Cheng A; Hoff NA; Mukadi P; Shidi C; Gerber S; Wemakoy EO; Muyembe-Tafum JJ; Kominski GF; Rimoin AW
Vaccine; 2017 Oct; 35(45):6187-6194. PubMed ID: 28966000
[TBL] [Abstract][Full Text] [Related]
3. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
[TBL] [Abstract][Full Text] [Related]
4. Review of regional measles surveillance data in the Americas, 1996-99.
Hersh BS; Tambini G; Nogueira AC; Carrasco P; de Quadros CA
Lancet; 2000 Jun; 355(9219):1943-8. PubMed ID: 10859039
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of providing measles vaccination to all children in Guinea-Bissau.
Byberg S; Fisker AB; Thysen SM; Rodrigues A; Enemark U; Aaby P; Benn CS; Griffiths UK
Glob Health Action; 2017; 10(1):1329968. PubMed ID: 28580855
[TBL] [Abstract][Full Text] [Related]
6. An economic evaluation of the current measles vaccination program: A case study in Zhejiang Province, east China.
Zeng Y; Luo M; Chen J; He H; Deng X; Xie S; Fang Y
Vaccine; 2019 May; 37(23):3071-3077. PubMed ID: 31040084
[TBL] [Abstract][Full Text] [Related]
7. Measles eradication: recommendations from a meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC.
MMWR Recomm Rep; 1997 Jun; 46(RR-11):1-20. PubMed ID: 9213745
[TBL] [Abstract][Full Text] [Related]
8. Measles elimination in the Americas.
Bull Pan Am Health Organ; 1992; 26(3):271-4. PubMed ID: 1356553
[TBL] [Abstract][Full Text] [Related]
9. Tenth Technical Advisory Group (TAG) meeting on vaccine-preventable diseases.
EPI Newsl; 1992 Apr; 14(2):2-6. PubMed ID: 12285738
[TBL] [Abstract][Full Text] [Related]
10. Current impact of measles in Latin America.
Borgoño JM
Rev Infect Dis; 1983; 5(3):417-21. PubMed ID: 6878992
[TBL] [Abstract][Full Text] [Related]
11. The economic disease burden of measles in Japan and a benefit cost analysis of vaccination, a retrospective study.
Takahashi K; Ohkusa Y; Kim JY
BMC Health Serv Res; 2011 Oct; 11():254. PubMed ID: 21978107
[TBL] [Abstract][Full Text] [Related]
12. Progress toward elimination of measles from the Americas.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1998 Mar; 47(10):189-93. PubMed ID: 9531021
[TBL] [Abstract][Full Text] [Related]
13. Progress toward measles eradication in the region of the Americas.
De Quadros CA; Izurieta H; Carrasco P; Brana M; Tambini G
J Infect Dis; 2003 May; 187 Suppl 1():S102-10. PubMed ID: 12721900
[TBL] [Abstract][Full Text] [Related]
14. Measles elimination in the Americas. Evolving strategies.
de Quadros CA; Olivé JM; Hersh BS; Strassburg MA; Henderson DA; Brandling-Bennett D; Alleyne GA
JAMA; 1996 Jan; 275(3):224-9. PubMed ID: 8604176
[TBL] [Abstract][Full Text] [Related]
15. Measles eradication: experience in the Americas.
de Quadros CA; Hersh BS; Nogueira AC; Carrasco PA; da Silveira CM
Bull World Health Organ; 1998; 76 Suppl 2(Suppl 2):47-52. PubMed ID: 10063674
[TBL] [Abstract][Full Text] [Related]
16. Economic analysis of investment priorities for measles control.
Shepard DS
J Infect Dis; 1994 Nov; 170 Suppl 1():S56-62. PubMed ID: 7930754
[TBL] [Abstract][Full Text] [Related]
17. Vaccination coverage rates for 1986.
Pan American Health Organization PAHO
EPI Newsl; 1987 Oct; 9(5):3-5. PubMed ID: 12315298
[TBL] [Abstract][Full Text] [Related]
18. Progress toward the 2012 measles elimination goal--Western Pacific Region, 1990-2008.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 Jun; 58(24):669-73. PubMed ID: 19553903
[TBL] [Abstract][Full Text] [Related]
19. Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: A cost-effectiveness analysis.
Zimmermann M; Frey K; Hagedorn B; Oteri AJ; Yahya A; Hamisu M; Mogekwu F; Shuaib F; McCarthy KA; Chabot-Couture G
Vaccine; 2019 Sep; 37(41):6039-6047. PubMed ID: 31471147
[TBL] [Abstract][Full Text] [Related]
20. Measles: not just another viral exanthem.
Duke T; Mgone CS
Lancet; 2003 Mar; 361(9359):763-73. PubMed ID: 12620751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
